Literature DB >> 23782585

Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.

Yan-Ling He, Kenneth Kulmatycki, Yiming Zhang, Wei Zhou, Christine Reynolds, Monica Ligueros-Saylan, Ann Taylor.   

Abstract

OBJECTIVE: The kidney plays a key role in both the metabolism and excretion of vildagliptin. This study was designed to investigate the effects of varying degrees of renal impairment (RI) on the pharmacokinetics of vildagliptin.
METHODS: A total of 96 subjects were enrolled, and each subject received vildagliptin 50 mg dosed orally once daily for 14 days. Vildagliptin and metabolite concentrations in plasma and urine were measured on Days 1 and 14.
RESULTS: Compared to age-, gender-, BMI-matched subjects with normal renal function, the mean AUC of vildagliptin after 14 days in patients with mild, moderate, and severe RI increased by 40%, 71%, and 100%, respectively, and the Cmax of vildagliptin showed similar and minimal increases of 37%, 32% and 36%, respectively.
CONCLUSIONS: These pharmacokinetics results suggest that 50 mg once daily is an appropriate dose and recommended for patients with moderate and severe renal impairment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23782585     DOI: 10.5414/CP201885

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  9 in total

Review 1.  Vildagliptin: a review of its use in type 2 diabetes mellitus.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 2.  Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

3.  Mechanistic Study on the Effect of Renal Impairment on the Pharmacokinetics of Vildagliptin and its Carboxylic Acid Metabolite.

Authors:  Zitao Guo; Fandi Kong; Ningjie Xie; Zhendong Chen; Jiafeng Hu; Xiaoyan Chen
Journal:  Pharm Res       Date:  2022-07-06       Impact factor: 4.580

Review 4.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23

5.  The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin.

Authors:  Florence Hui Sieng Tan; Chin Voon Tong; Xun Ting Tiong; Bik Kui Lau; Yueh Chien Kuan; Huai Heng Loh; Saravanan A/L Vengadesa Pillai
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-09-03

6.  Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.

Authors:  Se Hee Park; Joo Young Nam; Eugene Han; Yong-Ho Lee; Byung-Wan Lee; Beom Seok Kim; Bong-Soo Cha; Chul Sik Kim; Eun Seok Kang
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

7.  Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.

Authors:  Jun-Ichiro Mera; Eiko Okada; Masumi Okuda; Tatsuru Ota; Shigeru Sibata; Shunya Uchida
Journal:  J Diabetes Metab Disord       Date:  2015-11-05

Review 8.  Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.

Authors:  William David Strain; Päivi M Paldánius
Journal:  Eur Endocrinol       Date:  2017-08-22

Review 9.  Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance.

Authors:  Chantal Mathieu; Plamen Kozlovski; Päivi M Paldánius; James E Foley; Vikas Modgill; Marc Evans; Carmen Serban
Journal:  Eur Endocrinol       Date:  2017-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.